MA51675B1 - Compositions pharmaceutiques pour le traitement de la douleur postopératoire - Google Patents

Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Info

Publication number
MA51675B1
MA51675B1 MA51675A MA51675A MA51675B1 MA 51675 B1 MA51675 B1 MA 51675B1 MA 51675 A MA51675 A MA 51675A MA 51675 A MA51675 A MA 51675A MA 51675 B1 MA51675 B1 MA 51675B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
treatment
postoperative pain
amide
hyaluronic acid
Prior art date
Application number
MA51675A
Other languages
English (en)
Other versions
MA51675A (fr
Inventor
Andrea Pastorello
Fabio Bettella
Devis Galesso
Original Assignee
Fidia Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici S.P.A. filed Critical Fidia Farmaceutici S.P.A.
Publication of MA51675A publication Critical patent/MA51675A/fr
Publication of MA51675B1 publication Critical patent/MA51675B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques sous forme de gel comprenant une matrice hydrophile constituée d'un dérivé d'acide hyaluronique contenant un anesthésique local amide sous forme de base.
MA51675A 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire MA51675B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT201800001890A IT201800001890A1 (it) 2018-01-25 2018-01-25 Composizioni farmaceutiche per il trattamento del dolore postoperatorio
PCT/IB2019/050552 WO2019145863A1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire
EP19705572.6A EP3743043B1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Publications (2)

Publication Number Publication Date
MA51675A MA51675A (fr) 2021-04-28
MA51675B1 true MA51675B1 (fr) 2024-09-30

Family

ID=62089870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51675A MA51675B1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Country Status (17)

Country Link
US (1) US11357858B2 (fr)
EP (1) EP3743043B1 (fr)
KR (1) KR102819336B1 (fr)
CN (1) CN111629713B (fr)
AU (1) AU2019212448B2 (fr)
CA (1) CA3086650A1 (fr)
DK (1) DK3743043T3 (fr)
EA (1) EA202091613A1 (fr)
ES (1) ES2987059T3 (fr)
FI (1) FI3743043T3 (fr)
IT (1) IT201800001890A1 (fr)
LT (1) LT3743043T (fr)
MA (1) MA51675B1 (fr)
PL (1) PL3743043T3 (fr)
PT (1) PT3743043T (fr)
SA (1) SA520412416B1 (fr)
WO (1) WO2019145863A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192436A4 (fr) * 2020-08-10 2024-10-02 Ziropa, Inc. Compositions et procédés d'administration topique
JP2024519426A (ja) * 2020-09-29 2024-05-14 ジロパ・インコーポレイテッド 疼痛の緩和及び麻痺のための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
EP0859597B1 (fr) * 1995-09-29 2003-04-09 LAM Pharmaceutical Corporation Systeme d'administration a liberation prolongee et antagonistes et analgesiques narcotiques a effet de longue duree
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
IT1395392B1 (it) * 2009-08-27 2012-09-14 Fidia Farmaceutici Geli viscoelastici come nuovi filler
IT1401498B1 (it) * 2010-07-30 2013-07-26 Mero Srl Idrogelo a base di acido ialuronico e suo uso in ortopedia
EP2484387A1 (fr) * 2011-02-03 2012-08-08 Q-Med AB Composition d'acide hyaluronique
WO2015043757A1 (fr) * 2013-09-27 2015-04-02 Anteis S.A. Procédé d'obtention d'un hydrogel injectable à base d'aide hyaluronique contenant de la lidocaïne ajoutée sous forme pulvérulente, et un agent alcalin, stérilisé par la chaleur

Also Published As

Publication number Publication date
CN111629713A (zh) 2020-09-04
PL3743043T3 (pl) 2024-11-25
EA202091613A1 (ru) 2020-10-15
KR102819336B1 (ko) 2025-06-11
US11357858B2 (en) 2022-06-14
CN111629713B (zh) 2024-03-19
US20200360519A1 (en) 2020-11-19
EP3743043B1 (fr) 2024-07-24
IT201800001890A1 (it) 2019-07-25
DK3743043T3 (da) 2024-09-02
AU2019212448A1 (en) 2020-07-09
MA51675A (fr) 2021-04-28
AU2019212448B2 (en) 2024-08-15
EP3743043A1 (fr) 2020-12-02
LT3743043T (lt) 2024-10-25
KR20200113239A (ko) 2020-10-06
SA520412416B1 (ar) 2023-02-12
FI3743043T3 (fi) 2024-10-25
ES2987059T3 (es) 2024-11-13
PT3743043T (pt) 2024-09-19
WO2019145863A1 (fr) 2019-08-01
CA3086650A1 (fr) 2019-08-01

Similar Documents

Publication Publication Date Title
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
HRP20250148T1 (hr) Specifični triptamini za uporabu u liječenju poremećaja raspoloženja
EP3952902A4 (fr) Formes posologiques et schémas de traitement pour des composés d'acides aminés
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA56137B1 (fr) Sels de dihydrochlorure de valbénazine et leurs polymorphes
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
GEP20257840B (en) Tyk2 pseudokinase ligands
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
EP3806865A4 (fr) Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
MX2026000979A (es) Una forma farmaceutica solida de dosificacion bucodispersable de safinamida
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA50991B1 (fr) Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il
EP3632447A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse